Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study.
Hiroyuki NishiyamaToyonori TsuzukiChikara OhyamaHideyasu MatsuyamaKenta ShinozakiYuko HayashiNobuya HayashiRyo KotoEisei ShinOsamu OgawaPublished in: International journal of clinical oncology (2023)
PD-L1 expression and TMB were non-significant predictors of prognosis after first-line treatment in Japanese patients with mUC, but cancer-immune phenotype may be an important prognostic factor in chemotherapy-ICI sequential treatment strategies. Clinical trial registration number UMIN000037727.